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Abstract: A library of amine, oxime, ether, epoxy and acyl derivatives of the benzobicyclo[3.2.1]octene
were synthesized and evaluated as inhibitors of both human acetylcholinesterase (AChE) and
butyrylcholinesterase (BChE). The majority of the tested compounds exhibited higher selectivity for BChE.
Structural adjustment for AChE seems to have been achieved by acylation, and the furan ring opening of
furo-benzobicyclo[3.2.1]octadiene results for compound 51 with the highest AChE affinity (IC50 = 8.3 µM).
Interestingly, its analogue, an oxime ether with a benzobicyclo[3.2.1]-skeleton, compound 32 was one
of the most potent BChE inhibitors in this study (IC50 = 31 µM), but not as potent as endo-43, an ether
derivative of the benzobicyclo[3.2.1]octene with an additional phenyl substituent (IC50 = 17µM). Therefore,
we identified several cholinesterase inhibitors with a potential for further development as potential drugs
for the treatment of neurodegenerative diseases.
Keywords: acylation; benzobicyclo[3.2.1]octane/octene; benzylamines; cholinesterase;
epoxidation; oximes
1. Introduction
Acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase (BChE, EC 3.1.1.8), as they
control the acetylcholine ambient in the synapsis, are pharmacologically relevant enzyme targets
in neurodegenerative disorders [1,2]. AChE has an essential physiological role in the body as it
controls the transmission of nerve impulses in the cholinergic synapses of the central and peripheral
nervous system by hydrolysis of the neurotransmitter acetylcholine. Loss of neurons results in a
significant reduction in AChE and an increase in BChE levels in the brain [3,4]. BChE, even though
it is not physiologically essential, serves as a co-regulator of cholinergic neurotransmission capable
of catalyzing the hydrolysis of acetylcholine [5]. Except for cholinergic activity, cholinesterases are
associated with amyloid plaques and neurofibrillary tangles which together with the aggregation
of toxic amyloid-β peptide lead to the dysfunction and apoptosis of neurons [6–10]. Therefore,
compounds acting as inhibitors of cholinesterase could be considered as potential drugs in Alzheimer’s
disease (AD) treatment, other neurological disorders and therapeutics [11–15]. Due to the composition
of their active site, two enzymes can differ in selectivity and specificity for inhibitor binding [16–18].
Moreover, it has been well-documented that BChE reacts with a wider range of ligands than AChE and
is less selective [19–26].
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Recently we prepared photoproducts, shown in Figure 1, and probed the cholinesterase
inhibition [27,28]. Compounds endo-1 and endo-2 were the most potent inhibitors of AChE
(IC50 = 17.5 µM) and BChE (IC50 = 8.8 µM), respectively, among the tested compounds. All of
the tested photoproducts exhibited a binding preference for BChE. In comparison to huperzine A,
a selective BChE inhibitor (with similar basic methano-bridged aryl-bicyclo[3.3.1]octadiene skeleton),
compound endo-2 was about five times more potent as a BChE inhibitor [10].
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2. Results and Discussion 
2.1. Benzylic Amines with the Benzobicyclo[3.2.1]-Skeleton 
Chloro-substituted endo-1 (Scheme 1) was chosen as a suitable substrate for the 
Buchwald−Hartwig amination reaction. Compound endo-1 was obtained in one photochemical step 
according to the described method from the previously prepared o-vinylphenyl substituted 
butadienes [31]. The Buchwald−Hartwig amination successfully gave amino substituted 
benzobicyclo[3.2.1]octadienes endo-2–18 (Scheme 1) at 21%–88% yields [32]. 
Figure 1. Photoproducts as potent inhibitors of BChE and AChE [24].
The present study focused on the additional functionalization of the primary photoproducts to
obtain new amines, epoxides, alcohols and ethers (Figure 2A,B), or to find new oximes, oxime ethers
or acyl derivatives (Figure 2C,D). The mandatory postulate was high yield/productivity in the
photochemical reaction. That strategy resulted in a wide range of related compounds, four groups of
molecules with different functionalities and a common methano-bridged benzobicyclo[3.2.1]octadiene
skeleton found in huperzine A, many biologically active natural sesquiterpenoids [29] or similar to
bicyclo[3.2.1]octane benzylamines proven as potential neurokinin–1 antagonist drugs [30]. Compounds
were evaluated as inhibitors of both human AChE and BChE.
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(A) amines; (B) epox des, alcohols and ethers; (C) oximes and oxime ethers; and (D) acyl derivatives.
2. Results and Discussion
2.1. Benzylic Amines with the Benzobicyclo[3.2.1]-Skeleton
Chloro-substituted endo-1 (Scheme 1) was chosen as a suitable substrate for the Buchwald−Hartwig
amination reaction. Compound endo-1 was obt ined in one photochemical step ccording to
the described method from th previously prepar d o-vinylphenyl substituted butadienes [31].
The Buchwald−Hartwig amination successfully gave amino substituted benzobicyclo[3.2.1]octadien s
endo-2–18 (Scheme 1) at 21–88% yields [32].
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We tested 18 compounds described above as reversible inhibitors of human AChE and BChE
(Table 1), but it seems that benzobicyclo[3.2.1]octadiene benzylamines were poor inhibitors of both
cholinesterases. The exception was endo-10, a compound with methyl on the benzylamine substituent
in meta position, which seems important for the inhibition and binding interactions between BChE and
benzylamine. The rearranged products (1, 9, 17 and 20; Figure 3) were more potent BChE inhibitors than
endo-benzylamines of the bicyclo[3.2.1]octane skeleton. However, none of the compounds (≤100 µM)
showed potency to inhibit AChE. Unfortunately, in the case of AChE, due to the solvent interference,
we could not use a higher concentration.
2.2. Oxime Derivatives Possessing Benzobicyclo[3.2.1]-Skeleton
Further functionalization of the basic skeleton (Scheme 2) was performed according to the
synthesis of the formyl derivative [33], and a previously published study that combined docking and
density functional theory [34]. From the formyl derivative 21, the corresponding bicyclic oxime 22 was
synthesized as a crucial substrate for further synthesis of oxime ethers 22′. Along with the expected
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oxime 22 and oxime ethers 26–30, due to opening of the furan ring two classes were formed—opened
oximes 23–25 and oxime ethers 31–35 (Figure 4).
Table 1. Inhibition of BChE by benzobicyclo[3.2.1]octadiene benzylamines expressed as IC50 ± SEM.
Compound IC50/µM
endo-4 110 ± 77
endo-7 ≥500
endo-8 >500
endo-9 >500
endo-10 63 ± 13
endo-11 ≥500
endo-13 >500
endo-14 >500
endo-15 >500
endo-16 >500
endo-17 >500
endo-18 >500
endo-19 >500
endo-20 >500
1 260 ± 120
9 240 ± 210
17 120 ± 64
20 182 ± 98
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Oxime derivatives possessing a benzobicyclo[3.2.1]-skeleton (Figure 4) were prepared at sufficient
amounts and were tested as cholinesterase inhibitors. According to the results given in Table 2,
three different functionalities of compounds including oximes, oxime ethers with/without furan ring
seem highly related to inhibition potency. The lead inhibitors could be detected in each group, oxime 22
(IC50 = 25 ± 6 µM), oxime ether 28 with isopropyl group and furan ring (IC50 = 24 ± 3 µM) and oxime
ether 32 with an opened furan ring and isopropyl functionality (IC50 = 31 ± 4 µM). As for the presence
of the furan ring, it seems important only for the inhibition of BChE with oxime derivatives 22, 23,
24, and 25. In other words, IC50 for the opened oxime ether compounds was in the same range like
IC50 for furan-containing oxime ethers, as shown for compounds 28 and 32. However, IC50 decreased
for compounds with more saturated bicyclic moiety, e.g., octadiene 31 was a weaker inhibitor than
octene analogue 32. Compounds 27 and 29 differ only in the saturation of their chain substituent and
again propenyl derivative 29 inhibited slightly less potently than its propyl analogue 27. Moreover,
out of opened oxime ether derivatives (compounds 31–35), butenyl derivative 33 was the less potent
inhibitor. Therefore, the saturation of a compound can maybe play a crucial role for their beneficial
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interaction inside of the BChE active gorge. In case of AChE, none of the compounds were able to
inhibit more than 20% of enzyme with 200 µM concentration.
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Table 2. Inhibition of BChE by oximes and oxime ethers with benzobicyclo[3.2.1]-skeleton expressed as
IC50 ± SEM.
Compound IC50/µM
22 25 ± 6
23 450 ± 160
24 350 ± 100
25 >500
26 380 ± 250
27 74 ± 19
28 24 ± 3
29 00 ± 32
30 61 ± 36
31 90 ± 40
32 31 ± 4
33 140 ± 49
34 78 ± 31
35 60 ± 11
2.3. Epoxides, Alcohols and Ethers with Benzobicyclo[3.2.1]-Skeleton
Furt er functio alization of the benz bicyclo[3.2.1]octadiene skeleton was made through the
synt esis of novel epoxy erivatives, suitable substrates for novel alcohols and corresponding ethers.
It is worth mentioning that functionalization utilized the addition reaction to the free double bond
on the basic methano-bridged bicyclic skeleton. As it is known, epoxides represent three-membered
cyclic ethers of high reactivity an one way of synthesizing them is by epoxidation using per xy
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acids, which have an electrophilic oxygen atom, in a suitable solvent. This reaction represents a
stereospecific syn-addition to the double bond [35–37]. In this study, the reaction pathway to novel
epoxides, alcohols and ethers with the specific geometry (Scheme 3) began by obtaining corresponding
epoxides of photoproducts endo-36 and endo-37, and via alcohols the pathway led to desired ethers with
a benzobicyclo[3.2.1]octadiene structure. More specifically, the reaction of endo-36 and endo-37 with
meta-chloroperbenzoic acid (m-CPBA) in dichloromethane (DCM) as solvent gave the corresponding
epoxides endo-38 (61%) and endo-39 (50%). Although two stereoisomers could be obtained regarding
the oxygen position at the three-membered ring relative to the plane of the larger ring in the bridged
bicyclic system (Figure 5), we were unable to determine the exact stereochemistry of endo-38 and endo-39
by spectroscopic analysis (see experimental and SI, Figures S1–S19). Therefore, the stereochemistry
was predicted by DFT calculations (See SI).
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Th ring opening was carried out by reacting epoxides endo-38 and endo-39 and LiAlH4 in
tetrahydrofuran (THF; Scheme 3) as it is known that epoxides due to tension of the three-membered
ring are highly reactive. The resulting products of the reaction with reducing agent were alcohols
that can theoretically have four isomers: two regioisomers, and within them two more stereoisomers.
According to the literature, the most likely isomer, resulting from the epoxide opening product, is a
regioisomer with an hydroxy (OH) group on the middle carbon atom of the larger ring in the bridged
bicycle system [38]. Finally, the conversion of alcohol into different ethers was carried out by a
simple reaction of the alcohol with corresponding alkyl bromides and potassium carbonate in acetone
(Scheme 3). The isolated products (20%–50% yields) were characterized by spectroscopic methods
(see experimental and SI, Figures S1–S19).
Res lts on the biological activi y of obtained epoxides, alcohols and ethers with a benzobicyclo[3.2.1]-
skeleton in Table 3 show higher efficiency in the inhibition of both AChE and BChE than their counterparts.
Epoxide endo-38 as a highly reactive compound has proven to be a potent inhibitor for AChE even
though its potency was still 3-fold lower than for BChE. An opening of the epoxide ring resulted in
derivatives with higher selectivity of BChE, but the IC50 was only possible to evaluate for ether, endo-43,
or alcohol, endo-45, compounds without a substituent on the endo-oriented benzene ring. It seems that a
methoxy group in the para position on the phenyl substituent (endo-46 and endo-47) disturbed beneficial
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interactions for inhibition by a methoxy group as an electron-donating group. Interestingly, a study by
Mohammadi-Farani et al. with similar compounds containing a methoxy group in the meta position on the
phenyl ring, reported an increase of the inhibition potency for AChE [39]. Therefore, in the case of endo-46
and endo-47, their para-methoxy group probably could not achieve effective stabilization in the active site.
Table 3. Inhibition of human AChE and BChE by epoxides, alcohols and ethers possessing
benzobicyclo[3.2.1]-skeleton expressed as IC50 ± SEM.
Compounds
IC50/µM
AChE BChE
endo-38 62 ± 8 22 ± 5
endo-39 >100 33 ± 6
endo-43 >100 17 ± 2
endo-45 >100 90 ± 24
endo-46 270 ± 110 >500
endo-47 >100 >200
The Modelling of an Epoxide Ring Opening
To predict with more certainty which of the four possible alcohol isomers is dominant among
the products, we computationally modelled the reaction of an epoxide opening in molecule endo-38.
Calculations were performed at the (SMD)M06-2X/6-31G(d) level of theory in tetrahydrofuran as a
solvent, using Gaussian09 programme package [40]. The stationary points of reactions were localized
at the potential energy surface and vibrational analysis was performed to verify the minima and
transition states on the PES for all structures (See SI).
The epoxide opening step occurs upon the nucleophilic attack by a hydride anion at one of two
carbons that belong to the epoxide ring: the middle carbon of the larger ring in the bridged bicycle
system, denoted as B in Scheme 4, or the neighboring carbon atom denoted as A. A total of four
reactions may occur, two starting from structures where the oxygen of epoxide is placed above the
plane of the larger ring in the bridged bicycle system:
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Another two reactions, starting from the structure where an oxygen atom of epoxide is placed
below the plane are also possible (Scheme 5):Molecules 2020, 25, x FOR PEER REVIEW 8 of 25 
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Scheme 5. Two possible openings of epoxide, with oxygen positioned below the plane.
Reactions (1) and (3) lead to two stereoisomers of regioisomer where the hydroxyl group is placed
at the CA atom of the larger ring in the bridged bicycle system, while (2) and (4) give two stereoisomers
of an alternative regioisomer, with an OH group at the middle carbon atom of the larger ring (i.e., at CB).
The free energy profile for all four reactions (1)–(4) was calculated and is shown in Figure 6.
The barrier for the ring opening was the highest and almost the same for reactions (1) and (2)
(dotted lines, 93.0 and 92.7 kJ mol−1) where molecule endo-38 has an oxygen atom of the epoxide ring
above the plane (structure (a) in Figure 7). Reaction (4) had the lowest activation energy of 73.0 kJ mol−1,
meaning the fastest process among these four reactions was the ring opening which leads to the
formation of alcohol with an OH group at the CB and placed below the plane.
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Figure 7. Optimized structures of two stereoisomers of starting epoxide. Isomer (b) is thermodynamically
more stable than isomer (a) by –7.9 kJ mol−1.
Thermodynamically, although the sum of free energies of reactants showed that an epoxide
isomer with an oxygen above the plane was less stable compared to the other is mer (for 7.9 kJ mol−1),
this ratio was invers d when an adduct between endo-38 and hydride f rmed: the adduct containing
an isomer with an O above the plane becomes more stable (Figure 6). This makes the absolute b rr ers
for the ring ope ing shown by reactions (1) and (2) even higher, being 123.9 and 124.2 kJ mol−1,
respectively, lead to the conclusion that reactions (3) and (4), where the absolute barriers were
106.9 and 95.5 kJ mol−1, respectively, were favored. Due to the difference between ac ivation energies
for re ctions (3) and (4) (Figure 6, full line), the prod ct that was probably th most abundant in the
mixture wa a regioisomer of alcoho with an OH group at he CB atom and placed below the plane.
Optimized structur s f alcohols derived from products of reactio s (1) and (2) are show in
Figure 8, wh reas the structures of alcohols corresponding to products of reactions (3) and (4) are
depicted in Figure 9.
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Figure 8. Alcohols formed from products of reactions (1) and (2).
Figure 10 shows the aliphatic part of the 1H NMR spectrum of the isolated epoxy derivative
endo-38 in comparison with the corresponding starting endo-36. It can be seen that there was no
signal for protons on the sp2 carbon (between 5.00 and 6.50 ppm), which means that the double bond
was broken and the epoxy ring has been formed. Instead of the signals in the mentioned region,
new triplets can be seen at 3.45 and 3.39 ppm for protons A and B with coupling constants of 3.9 and
4.1 Hz, respectively.
The signal at 3.54 ppm was a doublet for the proton E with the coupling constant of 4.8 Hz. The triplet
and doublet at 3.07 and 2.99 ppm belonged to the signals of protons C and D with coupling constants of
5.0 and 4.1 Hz, respectively. Proton G showed a doublet at 2.41 ppm with a coupling constant of 10.8 Hz.
The signal at chemical shift 2.05 ppm was a multiplet belonging to proton F. The difference between the
signals of endo-38 and the corresponding ether endo-45 is the presence of an expected number of new
Molecules 2020, 25, 4872 10 of 24
signals in the aliphatic region for the new aliphatic chain as a substituent following the substitution of the
hydroxy proton. The same tendency can be seen for the methoxy derivatives starting with photoproduct
endo-37, corresponding epoxide endo-39 and ether endo-48 (Figure 11).
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Figure 9. Alcohols derived from products of reactions (3) and (4).
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Figure 10. Partial 1H NMR spectra of starting compound endo-36 and reaction products epoxyde
endo-38 and ether endo-45.
The stereochemistry on the reactive carbon was determined for some ethers according to their
NOESY spectra. From the NOESY spectrum of the ether endo-45 (Figure 12) the coupling of proton
F with protons E, D and G, protons A/A1 with protons C and B, and proton G with protons E and
D can be observed. The most significant coupling was of proton B with protons G and D within
known stereochemistry.
On th basis of the crucial interactions, it was concluded th t th obtained stereoisomer was one
in which the ether group was below the imaginary plane of the bicyclic skeleton. Accordingly, proton
B was located above the plane of the bicyclic skeleton. These conclusions were also confirmed by
calculations suggesting at the same time the stereochemistry of the corresponding alcohol endo-40 and
epoxide endo-38 for the synthesis of the final ethers according to Scheme 3.
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2.4. Friedel-Crafts Acylation of the Furo-Benzobicyclo[3.2.1]octadiene Photoproduct
Benzobicyclo[3.2.1]octadiene photoproduct 49 [41] with the annulated furan ring was the starting
substrate (Scheme 6) for syntheses of the fourth group of compounds (Figure 2D). The Friedel–Crafts
acylation reaction of 49 was performed with various carbonyl chlorides in the seal tube. During the
reaction under applied conditions, in all cases the furan ring of 49 opened to give novel mono- or dihydroxy
and mono- or dicarbonyl derivatives 50–57 (7–59%) with the characteristic benzobicyclo[3.2.1]-skeleton
(Figure 13).
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Figure 13. Isolated products of acylation reaction.
The structure and purity of the synthesized products of acylation were confirmed by NMR
techniques as well as High Resolution Mass Spectrometry (HRMS) analyses (see experimental and
Figure 14). In comparison with the aliphatic part of the proton NMR spectrum of 49 and characteristic
six signals, seven signals were present in the same region for compound 53. Together with the absence
of the singlet for the furyl proton but two new doublets with allylic coupling constants, the opening
of the heterocyclic ring as well as the structure were confirmed. However, as in the cases of several
derivatives, the formed tautomers were in an equilibrium, and the products were isolated at lower
amounts. Nevertheless, only two compounds from this group were tested as cholinesterase inhibitors.
Acylated furo-benzobicyclo[3.2.1]octadiene 51 exhibited the maximum of anti-AChE activity of
all of the tested compounds (Table 4). It seems that a smaller saturated molecule with two effective
nucleophile groups can contribute to interactions with the AChE active site. Even though compound 51
was not a potent inhibitor of BChE, its structure is similar to opened oxime ether 31 (Figure 4), a potent
inhibitor of BChE. However, none of tested compounds inhibited the enzymes in nanomolar range like
etopropazine, a drug for Parkinson’s disease [42].
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Figure 14. Partial 1H NMR spectra of starting und 49 and the acylation product 51 with the
opened furan ring.
Table 4. Inhibition of human AChE and BChE by acylated furo-benzobicyclo [3.2.1]octenes/octadienes
expressed as IC50 ± SEM.
Compound
IC50/µM
AChE BChE
51 8.3 ± 4.0 >300
53 188 ± 133 146 ± 30
Ethopropazine 73 ± 8.3 0.046 ± 0.037
3. Materials and Methods
3.1. General
Petroleum ether (PE)(VWR Prolabo Chemicals, Fontenay-sous-Bois, France), bp 40–60 ◦C, was used.
Solvents were purified by distillation. Column chromatography was carried out on columns with
silica gel (Fluka 0.063–0.2 nm and Fluka 60 Å, technical grade, Merck, New York, NY, USA). Thin layer
chromatography (TLC) was carried out using plates coated with silica gel (0.2 mm, 0.5 mm, 1.0 mm,
Kiselgel 60 F254, Merck, New York, NY, USA). Organic layers were routinely dried with anhydrous
MgSO4 and evaporated using a rotary evaporator (Heidolph, Schwabach, Germany). 1H and 13C NMR
spectra were recorded on a spectrometer (Bruker AV-600 Spectrometer, Billerica, MA, USA) at 600 MHz.
All NMR spectra were measured in CDCl3 using tetramethylsilane (Merck, New York, NY, USA)
as reference. The following abbreviations were used: Sh—shoulder (in UV spectra), s—singlet,
d—doublet, t—triplet, q—quartet, dd—doublet of doublets, m—multiplet, br—broad, PE—petroleum
ether, E—diethyl ether. UV spectra were measured on a UV/VIS spectrophotometer (Varian Cary
50 UV/VIS Spectrophotometer, Palo Alto, CA, USA). Mass spectra were obtained on a UPLC-MS
system (Acquity UPLC coupled with SQD mass spectrometer, Milford, MA, USA). Melting points
were obtained using a microscope equipped apparatus (Original Kofler Mikroheitztisch apparatus
Reichert, Vienna, Austria) and have not been corrected. HRMS analyses were carried out on a mass
spectrometer (MALDI TOF/TOF analyzer (Merck, New York, NY, USA), equipped with Nd:YAG laser
(Merck, New York, NY, USA) operating at 355 nm with a firing rate of 200 Hz in the positive (H+) or
negative (-H) ion reflector mode. Compounds endo-1, endo-36, endo-37 and 49 were prepared in our
laboratory by photochemical strategy and published before [31,41,43,44].
3.2. Photochemistry
Photochemical Synthesis of endo-1, endo-36 and endo-37
The solutions of a mixture of isomers of corresponding Wittig reaction products were purged
with argon for 20 min and irradiated at 350 nm in petroleum ether (5 × 10−3 M) in a Rayonet reactor in
Molecules 2020, 25, 4872 14 of 24
a Pyrex tube for 4 h. The solvent was removed in vacuum and the oily residue chromatographed on
silica gel column using petroleum ether as eluent.
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After column chromatography, 77% of endo-1, 90% of endo-36 and 70% of endo-37 was isolated.
High-molecular-weight products remained on the column.
11-(4-Chlorophenyl)tricyclo[6.3.1.0
2,7]dodeca-2,4,6,9-tetraene (endo-1) [39]: colorless oil; Rf 0.66
(petroleum ether/dichloromethane = 9:1); UV (96% EtOH)λmax (log ε) 276 (3.19), 268 (3.22), 224 (4.20, sh);
1H NMR (CDCl3, 600 MHz) δ/ppm 7.14 (d, J = 8.4 Hz, 2H, Har2), 7.12 (d, J = 7.3 Hz, 1H), 7.03 (td, J = 7.4;
1.0 Hz, 1H), 6.84 (td, J = 7.4; 1.0 Hz, 1H), 6.65 (d, J = 8.3 Hz, 2H, Har1), 6.40–6.35 (m, 1H, HA),
6.23 (d, J = 7.3 Hz, 1H, Har), 5.25 (ddd, J = 9.6; 4.0; 1.9 Hz, 1H, HB), 3.96–3.92 (m, 1H), 3.34 (t, J = 9.4;
4.7 Hz, 1H), 3.29 (dd, J = 6.1; 4.7 Hz, 1H), 2.54–2.50 (m, 1H, HF), 2.37 (d, J = 10.0 Hz, 1H, HG); 13C NMR
(CDCl3, 150 MHz) δ/ppm 140.6 (s), 137.3 (s), 132.9 (s), 130.9 (s), 134.7 (d), 129.2 (2d), 127.3 (d), 125.7 (d),
125.6 (d), 125.4 (2d), 124.7 (d), 119.7 (d), 48.0 (d), 45.3 (d), 43.7 (t), 39.9 (d); HRMS (m/z) for C18H15Cl:
[M + H]+calcd = 265.0789, [M + H]+measured = 265.0786.
endo-6-Phenyl-6,9-dihydro-5H-5,9-methano-benzocycloheptene (endo-36) [38]: colorless crystals; mp 51 ◦C;
Rf 0.44(petroleum ether); UV (EtOH)λmax (logε) 275 (2.88), 263 (2.90), 203 (4.46); 1H NMR (CDCl3, 600 MHz)
δ7.17–7.18 (m, 3H, Hf), 7.12 (d, J = 7.3 Hz, 1H, HAr4), 7.03 (t, J = 7.4 Hz, 1H, HAr3), 6.81 (t, J = 7.4 Hz,
1H, HAr2), 6.73–6.76 (m, 2H, Hf1), 6.37 (ddd, JAB = 9.5 Hz; JAE = 6.0 Hz; JAC = 2.5 Hz, 1H, HA),
6.18 (d, J = 7.3 Hz, 1H, HAr1), 5.33 (dt, JAB = 9.5 Hz; JBC = 2.5 Hz, 1H, HB), 3.98 (m, 1H, HC), 3.38
(t, JCD = JDF = 4.7 Hz, 1H, HD), 3.29 (dd, JAE = 6.0 Hz; JEF = 4.7 Hz, 1H, HE), 2.52 (dt, JFG = 9.9 Hz;
JEF = JDF = 4.7 Hz, 1H, HF), 2.38 (d, JFG = 9.9 Hz, 1H, HG); 13C NMR (CDCl3, 150 MHz) δ152.27 (s),
142.44 (s), 141.93 (s), 132.71 (d), 128.21 (d), 127.60 (d), 126.34 (d), 126.10 (d), 126.05 (d), 125.97 (d), 124.89 (d),
120.03 (d), 48.59 (d), 46.29 (d), 44.13 (t, CFG), 40.37 (d); MS m/z (EI) 232 (M+, 100%), 117 (25), 115 (10); HRMS
(m/z) for C18H16: [M + H]+calcd = 232.1634, [M + H]+measured = 232.1655.
11-(4-Methoxyphenyl)tricyclo[6.3.1.0
2,7]dodeca-2,4,6,9-tetraene (endo-37) [40]: colorless crystals;
mp 45–47 ◦C; Rf (petroleum ether/dichloromethane = 8:2) = 0.27; 1H NMR (CDCl3, 600 MHz)
δ/ppm: 7.11 (d, 1H, J = 7.3 Hz), 7.03 (dt, 1H, J = 7.3; 1.0 Hz), 6.82 (dt, 1H, J = 7.3; 1.0 Hz), 6.72 (d, 2H,
J = 8.6 Hz), 6.64 (d, 2H, J = 8.6 Hz), 6.32-6.36 (m, 1H), 6.25 (d, 1H, J = 7.3 Hz), 5.28 (dt, 1H, J = 9.6; 2.6 Hz),
3.91–3.94 (m, 1H), 3.77 (s, 3H), 3.35 (t, 1H, J = 4.5 Hz), 3.27 (dd, 1H, J = 6.3; 4.7 Hz), 2.49–2.53 (m, 1H),
2.37 (d, 1H, J = 9.9 Hz); 13C NMR (CDCl3, 75 MHz) δ/ppm: 157.6 (s), 152.0 (s), 141.7 (s), 134.2 (s),
134.1 (d), 128.8 (2d), 126.3 (d), 125.8 (d), 125.5 (d), 124.5 (d), 119.6 (d), 112.6 (2d), 52.4 (q), 48.2 (d),
45.0 (d), 43.7 (t), 40.3 (d); MS m/z (%, fragment): 262 (100, M+), 154 (75), 115 (50); HRMS (m/z) for
C19H18O: [M + H]+calcd = 262.1352, [M + H]+measured = 262.1351.
3.3. Synthesis of Benzylamine Derivatives
Amination Reactions of endo-1 with Primary Benzylic Amines
To a solution of BrettPhos (0.1 eq) and Pd(OAc)2 (0.05 eq) in dioxane, 4% of water was added.
After the addition of water, the solution was heated to 120 ◦C for 2 min. The reaction mixture
changed color from light yellow, over dark red to dark green. Compound endo-1, different amine
(2 eq) and KOtBu (1.4 eq) were added into a sealed tube. The reaction mixture was stirred for 20 h on
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180 ◦C. After the removal of the solvent, the crude product residue was purified by repeated column
chromatography using petroleum ether/dichlorometane mixture as an eluent. All of the obtained
compounds endo-4–20 were isolated in the first fractions as yellow oils, while BrettPhos remained on
the chromatographic column. In all cases, the conversion of the amination reaction was complete.
The spectroscopic data for some of the previously synthesized amines (endo-4, endo-6, endo-7 and endo-8)
are given below.
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N-Benzyl-4-((5R,6S,9S)-6,9-dihydro-5H-5,9-methanobenzo[7]annulen-6-yl)aniline (endo-4): Column
chromatography on silica gel using petroleum ether/dichloromethane (0%–60%) as eluent afforded
0.080 g (48.3%) of endo-4: Rf (PE / DCM = 5:1) = 0.43; UV (EtOH) λmax/nm (ε/dm3mol−1cm−1):
251 (11,312), 306 (Sh, 2527); IR νmax/cm−1 (diamond ATR): 3408.78, 1613.45, 1517.61, 1468.98; 1H NMR
(CDCl3, 600 MHz) δ/ppm: 7.38–7.25 (m, 5H), 7.10 (d, 1H, J = 7.4 Hz), 7.02 (dt, 1H, J = 7.4; 1.1 Hz),
6.83 (dt, 1H, J = 7.4; 1.1 Hz), 6.54 (d, 2H, J = 8.6 Hz), 6.47 (d, 2H, J = 8.6 Hz), 6.32 (d, 2H, J = 7.4 Hz,
Har, HA), 5.27 (td, 1H, J = 9.5; 1.9 Hz, HB), 4.28 (s, 2H), 3.92–3.85 (m, 2H, HC, NH), 3.35 (t, 1H,
J = 4.2 Hz, HD), 3.27 (dd, 1H, J = 6.3; 4.2 Hz, HE), 2.55–2.47 (m, 1H, HF), 2.34 (d, 1H, J = 10.1 Hz, HG);
13C NMR (CDCl3, 150 MHz) δ/ppm: 152.1 (s), 146.1 (s), 141.9 (s), 139.1 (s), 133.8 (d), 130.6 (s), 128.6
(2d), 128.1 (d), 128.1 (d), 127.1 (d), 126.7 (2d), 126.0 (d), 125.9 (d), 125.4 (d), 124.4 (d), 119.5 (d), 111.9
(2d), 48.4 (d), 48.2 (t), 45.2 (d), 43.7 (t), 40.0 (d); MS m/z (%, fragment): 337 (100, M+); HRMS (m/z) for
C25H23N: [M + H]+calcd = 338.1822, [M + H]+measured = 338.1902.
4-((5R,6S,9S)-6,9-Dihydro-5H-5,9-methanobenzo[7]annulen-6-yl)-N-(pyridin-3-ylmethyl)-aniline
(endo-6): Column chromatography on silica gel using dichloromethane/ethanol (variable ratio)
as eluent afforded 0.062 g (21.2%) of endo-6 in the first fractions: Rf (DCM) = 0.1; UV (EtOH) λmax/nm
(ε/dm3mol−1cm−1): 254 (15,991); IR νmax/cm−1 (diamond ATR): 3370.11, 1609.55, 1531.76, 1444.89;
1H NMR (CDCl3, 600 MHz) δ/ppm: 8.62 (s, 1H), 8.52 (dd, 1H, J = 5.4; 1.3 Hz), 7.67 (d, 1H, J = 7.4 Hz),
7.30–7.23 (m, 3H), 7.13 (d, 1H, J = 7.4 Hz), 7.09 (dt, 1H, J = 7.7; 1.2 Hz), 7.03 (dt, 1H, J = 7.7; 1.2 Hz),
6.85 (d, 1H, J = 8.5 Hz), 6.83 (d, 2H, J = 8.5 Hz), 6.60-6.58 (m, 2H, Har, HA), 5.41 (t, 1H, J = 3.7 Hz, HB),
4.36 (s, 2H), 3.79–3.76 (m, 2H, HC, NH), 3.32 (t, 1H, J = 5.1 Hz, HD), 2.69 (td, 1H, J = 8.3; 1.2 Hz, HE),
(signal for HF and HG can’t be assigned because of the presence of the catalyst BrettPhos); MS m/z
(%, fragment): 338 (100, M+).
Column chromatography on silica gel using dichloromethane/ethanol (variable ratio) as eluent
afforded 0.051 g (43.8%) of endo-7 and 0.064 g (51.5%) of endo-8.
4-((5R,6S,9S)-6,9-Dihydro-5H-5,9-methanobenzo[7]annulen-6-yl)-N-(fur-2-ylmethyl)aniline (endo-7):
Rf (PE / DCM = 5:1) = 0.62; UV (EtOH) λmax/nm (ε/dm3mol−1cm−1): 255 (28,024), 358 (12,474);
IR νmax/cm−1 (diamond ATR): 3412.68, 1603.44, 1517.61, 1468.98; 1H NMR (CDCl3, 600 MHz) δ/ppm:
7.34 (d, 1H, J = 1.6 Hz, H5f), 7.09 (d, 1H, J = 7.2 Hz), 7.00 (t, 1H, J = 7.4 Hz), 6.80 (t, 1H, J = 7.2 Hz),
6.53 (d, 2H, J = 8.5 Hz), 6.49 (d, 2H, J = 8.5 Hz), 6.33–6.24 (m, 3H, Har, HA), 6.20 (d, 1H, J= 3.2 Hz, H3f),
5.26 (d, 1H, J = 9.4 Hz, HB), 4.26 (s, 2H), 3.88–3.83 (m, 1H, HC), 3.31 (t, 1H, J = 4.8 Hz, HD), 3.24 (t, 1H,
J = 4.8 Hz, HE), 2.51–2.43 (m, 1H, HF), 2.33 (d, 1H, J = 9.7 Hz, HG); 13C NMR (CDCl3, 150 MHz) δ/ppm:
152.9 (s), 152.5 (s), 146.0 (s), 142.3 (s), 141.8 (d), 134.3 (d), 132.2 (s), 129.1 (2d), 121.1 (d), 126.4 (d), 125.9 (d),
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124.9 (d), 119.9 (d), 112.8 (2d), 110.2 (d), 106.9 (d), 48.8 (d), 45.7 (d), 44.1 (t), 40.5 (d); MS m/z (%, fragment):
327 (100, M+); HRMS (m/z) for C23H21NO: [M + H]+calcd = 328.1609, [M + H]+measured = 328.1689.
4-((5R,6S,9S)-6,9-dihydro-5H-5,9-methanobenzo[7]annulen-6-yl)-N-(thien-2-ylmethyl)aniline (endo-8):
Rf (PE / DCM = 5:1) = 0.70; UV (EtOH) λmax/nm (ε/dm3mol−1cm−1): 247 (18,373); IR νmax/cm−1
(diamond ATR): 3413.17, 1613.45, 1516.18, 1468.98; 1H NMR (CDCl3, 600 MHz) δ/ppm: 7.48 (d, 1H,
J = 4.9 Hz) 7.38 (d, 1H, J = 7.2 Hz), 7.30 (t, 1H, J = 7.1 Hz), 7.27 (broad s), 7.25–7.22(m, 2H),
7.11 (t, 1H, J = 7.2 Hz), 6.83 (d, 2H, J = 8.6 Hz), 6.78 (d, 2H, J = 8.6 Hz), 6.62-6.56 (m, 2H, Har, HA),
5.55 (d, 1H, J = 9.5 Hz, HB), 4.75 (s, 2H), 4.20–4.13 (m, 2H, HC, NH), 3.61 (t, 1H, J = 4.7 Hz, HD),
3.53 (t, 1H, J = 4.7 Hz, HE), 2.79–2.74 (m, 1H, HF), 2.62 (d, 1H, J = 9.7 Hz, HG);13C NMR (CDCl3,
150 MHz) δ/ppm: 152.5 (s), 145.9 (s), 143.1 (s), 142.3 (s), 134.4 (d), 132.3 (s), 129.1 (2d), 127.1 (d), 126.7 (d),
126.4 (d), 125.8 (d),125.0 (d), 124.9(d), 124.5 (d), 119.9 (d), 112.7 (2d), 48.8 (d), 45.7 (d), 44.1 (t), 43.7 (t),
40.4 (d); MS m/z (%, fragment): 343 (100, M+); HRMS (m/z) for C23H21NS: [M + H]+calcd = 344.1394,
[M + H]+measured = 344.1474.
3.4. Synthesis of Oxime Derivatives
3.4.1. Synthesis of Oxime
A mixture of aldehyde 21 (0.223 mmol), hydroxylamine hydrochloride (0.112 mmol, 0.5 eq),
and pyridine (0.05 mL) was refluxed in ethanol (1 mL) for 1 h on a water bath. Completion of the
reaction was checked by TLC (DCM/PE, 1:3). At the end of the reaction, ethanol was evaporated to
dryness. Crude material was purified on column chromatography using different polarity of solvents.
The product was additionally purified using preparative TLC (DCM/PE).
3.4.2. Synthesis of Oxime Ethers
A solution of oxime 22 (0.251 mmol) and alkyl bromide (0.276 mmol, 1.1 eq) in dry acetone (2 mL)
was refluxed in the presence of dry potassium carbonate (0.376 mmol, 1.5 eq) for 48 h on a water bath.
Completion of the reaction was checked by TLC (DCM/PE). At the end of the reaction, acetone was
evaporated to dryness. Crude material was purified on column chromatography using different
polarity of solvents (DCM/PE) and the product was also additionally purified using preparative TLC.
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(4R,9R)-9,10-Dihydro-4H-4,9-methanobenzo[4,5]cyclohepta[1,2-b]furan-2-carbaldehyde (21) [33]: 180 
mg (50.0%); Rf (petroleum ether/dichloromethane = 20:1) = 0.23; UV (EtOH) λmax (/dm3 mol−1 cm−1): 
308 (16794) nm;IR max/cm−1 (NaCl): 1666, 1504; 1H NMR (CDCl3, 300 MHz) /ppm: 9.41 (s, 1H), 7.32 
(dd, 1H, J = 7.2; 1.4 Hz), 7.16–7.08 (m, 4H, 3H), 3.91 (d, 1H, J = 4,4 Hz, HA), 3.66 (dt, 1H, J = 4.9; 0.5 Hz, 
HB), 3.20 (dd, 1H, J = 17.8; 4.9 Hz, HC), 2.72 (dd, 1H, J = 17.8; 0.5 Hz, HD), 2.48 (ddd, 1H, J = 10.7; 4.9; 
4.4 Hz, HE), 2.4 (d, 1H, J = 10.7 Hz, HF); 13C NMR (CDCl3, 75 MHz)  /ppm: 176.6 (d), 156.0 (s), 151.3 
(s), 150.6 (s), 144.1 (s), 128.5 (s), 126.9 (d), 126.9 (d), 124.1 (d), 121.0 (2d), 42.5 (t), 39.6 (d), 39.1 (d), 31.4 
(t); MS m/z (%, fragment): 224 (100, M+), 167 (75), 115 (50); HRMS (m/z) for C19H18O: [M + H]+calcd = 
224.3355, [M + H]+measured = 224.3347. 
(E)-9,10-Dihydro-4H-4,9-methanobenzo[4,5]cyclohepta[1,2-b]furan-2-carbaldehyde oxime (22): 16.3 mg 
(40%); Rf (PE / DCM = 1:1) = 0.33; IR max/cm−1 (NaCl): 3400, 2943, 1668, 1613, 1572, 1503, 1460; 1H NMR 
(CDCl3, 600 MHz) /ppm: 7.36 (d, 1H, J = 6.6 Hz), 7.18-7.05 (m, 4H), 6.06 (s, 1H), 4.62 (d, 1H, J = 2.5 
Hz), 3.81 (d, 1H, J = 4.0 Hz), 3.59-3.54 (m, 2H), 2.40-2.37 (m, 2H); 13C NMR (CDCl3, 150 MHz) /ppm: 
152.1 (s), 146.6 (s), 141.9 (s), 135.9 (s), 131.6 (s), 126.9 (d), 126.4 (d), 125.1 (d), 121.5 (d), 104.6 (2d), 67.4 
(t), 48.9 (d), 39.7 (t), 39.6 (d); MS m/z (%, fragment) (EI): 239 (100); HRMS (m/z) for C19H19ON: [M + H]+ 
calcd = 240.0946; [M + H]+measured = 240.0941. 
(Z)-9,10-Dihydro-4H-4,9-methanobenzo[4,5]cyclohepta[1,2-b]furan-2-carbaldehyde O-propyl oxime 
(27): 13.6 mg (32%); Rf (PE / DCM = 1:5) = 0.55; IR max/cm−1 (NaCl): 3434, 2918, 1731, 1638, 1234; 1H 
NMR (CDCl3, 600 MHz) /ppm: 7.32 (d, 1H, J = 7.4 Hz), 7.19–7.07 (m, 4H), 6.94 (s, 1H), 3.86 (d, 1H, J 
= 4.5 Hz), 3.68 (d, 1H, J = 5.0 Hz), 3.48 (q, 2H, J = 7.0 Hz), 3.15 (dd, 1H, J = 17.4; 5.0 Hz), 2.67 (dd, 1H, J 
= 17.4; 1.3 Hz), 2.51–2.47 (m, 1H), 2.03 (d, 1H, J = 11.2 Hz), 1.34–1.29 (m, 2H), 0.88 (t, 3H, J = 6.9 Hz); 
13C NMR (CDCl3, 150 MHz) /ppm: 152.0 (s),150.5 (s), 143.8 (s), 135.6 (s), 128.1 (s), 126.9 (d), 126.9 (d), 
124.1 (d), 124.1 (d), 120.2 (d), 67.0 (t), 42.5 (t), 39.6 (d), 38.9 (d), 31.2 (t), 29.6 (t), 22.7 (q); MS m/z (%, 
fragment) (EI): 281 (100); HRMS (m/z): [M + H]+ calcd = 282.1416; [M + H]+measured = 282.1419. 
3.5. Synthesis of Epoxide Derivatives 
Synthesis of (2R,7R,8S,8aS)-8-phenyl-1a,7,8,8a-tetrahydro-2H-2,7-methanobenzo[4,5]cyclohepta[1,2-
b]oxirene (endo-38) and (2R,7R,8S,8aS)-8-(4-methoxyphenyl)-1a,7,8,8a-tetrahydro-2H-2,7-
methanobenzo[4,5]cyclohepta[1,2-b]oxirene (endo-39) 
Epoxide derivatives endo-38 and endo-39 were prepared by epoxidation reaction using meta-
chlorperbenzoic acid (m-CPBA). Photoproducts endo-36 and endo-37 were dissolved in 20 mL dry 
dioxane, and m-CPBA was added. The reaction mixture was stirred at room temperature overnight. 
After the reaction was complete, the saturated water solution of NaHCO3 was added. The organic 
(4R,9R)-9,10-Dihydro-4H-4,9-methanobenzo[4,5]cyclohepta[1,2-b]furan-2-carbaldehyde (21) [33]: 180 mg
(50.0%); Rf (petroleum ether/dichloromethane = 20:1) = 0.23; UV (EtOH) λmax (ε/dm3 mol−1 cm−1):
308 (16794) nm; IR νmax/cm−1 (NaCl): 1666, 1504; 1H NMR (CDCl3, 300 MHz) δ/ppm: 9.41 (s, 1H),
7.32 (dd, 1H, J = 7.2; 1.4 Hz), 7.16–7.08 (m, 4H, 3H), 3.91 (d, 1H, J = 4,4 Hz, HA), 3.66 (dt, 1H, J = 4.9;
0.5 Hz, HB), 3.20 (dd, 1H, J = 17.8; 4.9 Hz, HC), 2.72 (dd, 1H, J = 17.8; 0.5 Hz, HD), 2.48 (ddd, 1H,
J = 10.7; 4.9; 4.4 Hz, HE), 2.4 (d, 1H, J = 10.7 Hz, HF); 13C NMR (CDCl3, 75 MHz) δ /ppm: 176.6 (d),
156.0 (s), 151.3 (s), 150.6 (s), 144.1 (s), 128.5 (s), 126.9 (d), 126.9 (d), 124.1 (d), 121.0 (2d), 42.5 (t), 39.6 (d),
39.1 (d), 31.4 (t); MS m/z (%, fragment): 224 (100, M+), 167 (75), 115 (50); HRMS (m/z) for C19H18O:
[M + H]+calcd = 224.3355, [M + H]+measured = 224.3347.
(E)-9,10-Dihydro-4H-4,9-methanobenzo[4,5]cyclohepta[1,2-b]furan-2-carbaldehyde oxime (22): 16.3 mg
(40%); Rf (PE / DCM = 1:1) = 0.33; IR νmax/cm−1 (NaCl): 3400, 2943, 1668, 1613, 1572, 1503, 1460;
1H NMR (CDCl3, 600 MHz) δ/ppm: 7.36 (d, 1H, J = 6.6 Hz), 7.18-7.05 (m, 4H), 6.06 (s, 1H), 4.62 (d, 1H,
J = 2.5 Hz), 3.81 (d, 1H, J = 4.0 Hz), 3.59-3.54 (m, 2H), 2.40-2.37 (m, 2H); 13C NMR (CDCl3, 150 MHz)
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δ/ppm: 152.1 (s), 146.6 (s), 141.9 (s), 135.9 (s), 131.6 (s), 126.9 (d), 126.4 (d), 125.1 (d), 121.5 (d), 104.6 (2d),
67.4 (t), 48.9 (d), 39.7 (t), 39.6 (d); MS m/z (%, fragment) (EI): 239 (100); HRMS (m/z) for C19H19ON:
[M + H]+ calcd = 240.0946; [M + H]+measured = 240.0941.
(Z)-9,10-Dihydro-4H-4,9-methanobenzo[4,5]cyclohepta[1,2-b]furan-2-carbaldehyde O-propyl oxime (27):
13.6 mg (32%); Rf (PE / DCM = 1:5) = 0.55; IR νmax/cm−1 (NaCl): 3434, 2918, 1731, 1638, 1234; 1H NMR
(CDCl3, 600 MHz) δ/ppm: 7.32 (d, 1H, J = 7.4 Hz), 7.19–7.07 (m, 4H), 6.94 (s, 1H), 3.86 (d, 1H, J = 4.5 Hz),
3.68 (d, 1H, J = 5.0 Hz), 3.48 (q, 2H, J = 7.0 Hz), 3.15 (dd, 1H, J = 17.4; 5.0 Hz), 2.67 (dd, 1H, J = 17.4;
1.3 Hz), 2.51–2.47 (m, 1H), 2.03 (d, 1H, J = 11.2 Hz), 1.34–1.29 (m, 2H), 0.88 (t, 3H, J = 6.9 Hz); 13C NMR
(CDCl3, 150 MHz) δ/ppm: 152.0 (s),150.5 (s), 143.8 (s), 135.6 (s), 128.1 (s), 126.9 (d), 126.9 (d), 124.1 (d),
124.1 (d), 120.2 (d), 67.0 (t), 42.5 (t), 39.6 (d), 38.9 (d), 31.2 (t), 29.6 (t), 22.7 (q); MS m/z (%, fragment) (EI):
281 (100); HRMS (m/z): [M + H]+ calcd = 282.1416; [M + H]+measured = 282.1419.
3.5. Synthesis of Epoxide Derivatives
Synthesis of (2R,7R,8S,8aS)-8-Phenyl-1a,7,8,8a-tetrahydro-2H-2,7-methanobenzo[4,5]cyclohepta[1,2-b]
oxirene (endo-38) and (2R,7R,8S,8aS)-8-(4-Methoxyphenyl)-1a,7,8,8a-tetrahydro-2H-2,7-methanobenzo
[4,5]cyclohepta[1,2-b]oxirene (endo-39)
Epoxide derivatives endo-38 and endo-39 were prepared by epoxidation reaction using meta-
chlorperbenzoic acid (m-CPBA). Photoproducts endo-36 and endo-37 were dissolved in 20 mL dry
dioxane, and m-CPBA was added. The reaction mixture was stirred at room temperature overnight.
After the reaction was complete, the saturated water solution of NaHCO3 was added. The organic
layer was washed twice with water and dried over MgSO4, filtered and evaporated to obtain crude
material. The crude material was purified using column chromatography.
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4.1 Hz, HA), 3.39 (t, 1H, J = 3.9 Hz, HB), 3.07 (d, 1H, J = 4.1 Hz, HC), 2.99 (t, 1H, J = 5.0 Hz, HD), 2.41 (d, 
1H, J = 10.8 Hz, HG), 2.0–2.02 (m, 1H, HF);13C NMR (cdcl3, 75 mhz) /ppm: 144.6 (s), 143.2 (s), 141.2 (s), 
133.2 (d), 129.3 (d), 128.2 (2d), 127.3 (2d), 126.4 (d), 125.3 (d), 122.1 (d), 54.1 (d), 52.5 (d), 45.8 (d), 43.2 
(t), 40.1 (d), 34.9 (t); MS m/z (%, fragment) (EI): 248; HRMS (m/z) for C18H16O: [M + H]+calcd = 249.1201, 
[M + H]+measured = 249.1190. 
(2R,7R,8S,8as)-8-(4-Methoxyphenyl)-1a,7,8,8a-tetrahydro-2H-2,7-methanobenzo[4,5]cyclohepta[1,2-
b]oxirene (endo-39):Yield 50%; Rf (petroleum ether): 0.13; 1H NMR (CDCl3, 600 MHz) /ppm: 7.29 (d, 
1H, J = 7.3 Hz, Ar), 7.16 (t, 1H, J = 7.2 Hz, Ar), 6.95 (t, 1H, J = 7.2 Hz, Ar), 6.75 (d, 2H, J = 8.3 Hz, Ar), 
6.61 (d, 2H, J = 8.3 Hz, Ar), 6.32 (d, 1H, J = 7.3 Hz, Ar), 3.79 (s, 3H, OCH3), 3.48 (d, 1H, J = 5.0 Hz, HE), 
3.44 (t, 1H, J = 4.0 Hz, HA), 3.36 (t, 1H, J = 3.8 Hz, HB), 3.00 (d, 1H, J = 4.0 Hz, HC), 2.95 (t, 1H, J = 5.0 
Hz, HD), 2.38 (d, 1H, J = 10.8 Hz, HG), 2.05–2.00 (m, 1H, HF); 13C NMR (CDCl3, 150 MHz) /ppm: 152.5 
(s), 142.9 (s), 135.9 (s), 133.8 (s), 129.6 (2d), 126.8 (d), 126.7 (d), 125.8 (d), 122.5 (d), 113.8 (2d), 55.2 (d), 
54.2 (d), 53.2 (q), 44.8 (d), 42.9 (t), 40.6 (d), 35.3 (d);MS m/z (%, fragment) (EI): 278; HRMS (m/z) for 
C19H16O2: [M + H]+calcd = 279.1306, [M + H]+measured = 279.1325. 
3.6. Epoxide Ring Opening 
To a solution of starting epoxide (0.8g) in THF, lithium aluminum hydride (2.5 eq) was added. 
The reaction mixture was stirred at 76 C during 24h. After the reaction was complete, NaHCO3 was 
added and pH was adjusted to 7. The water layer was washed twice with diethyl ether. Organic 
layers were dried over MgSO4, filtered and evaporated to obtain crude material. Crude material was 
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(6S)-6-Phenyl-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]anulen-7-ol (endo-40): Yield 40%; Rf 
(petroleum ether/ dichloromethane 40%): 0.20; 1H NMR (CDCl3, 600 MHz) /ppm 8.00–7.30 (m, 4H, 
Ar), 6.93–6.20 (m, 5H, Ar), 4.13 (m, 1H, HB) 3.40 (dd, 1H, J = 12.7, 4.7 Hz, HA/A1/E) 3.20 (t, 1H, J = 4.5 Hz, 
HA/A1/E), 3.14 (d, 1H, J = 4.5 Hz, HA/A1/E), 2.56 (d, 1H, J = 10.8 Hz, HG), 2.35 (s, 1H, OH), 2.25–2.20 (m, 
1H, HF) 1.63 (d, 1H, J = 4.8 Hz, HC/D), 1.60 (d, 1H, J = 4.8 Hz, HC/D); 13C NMR (CDCl3, 150 MHz) /ppm: 
143.8 (s), 142.3 (s), 133.9 (s), 129.3 (d), 128.9 (d), 127.6 (d), 127.2 (2d), 126.5 (d), 124.3 (2d), 122.1 (d), 
(2R,7R,8S)-8-Phenyl-1a,7,8,8a-tetrahydro-2H-2,7-methanobenzo[4,5]cyclohepta[1,2-b]-oxirene (endo-38):
Yield 61%; Rf (petroleum ether/dichloromethane): 0.27; 1H NMR (cdcl3, 600 mhz) δ/ppm: 7.53 (d, 2H,
J = 8.8 Hz, Ar), 7.30 (d, 1H, J = 7.4 Hz, Ar), 7.16 (t, 2H, J = 7.3 Hz, Ar), 6.93 (t, 1H, J = 7.3 Hz, Ar),
6.70 (dd, 2H, J = 8.8; 7.3 Hz, Ar), 6.26 (d, 1H, J = 7.4 Hz, Ar), 3.54 (d, 1H, J = 4.8 Hz, HE), 3.45 (t, 1H,
J = 4.1 Hz, HA), 3.39 (t, 1H, J = 3.9 Hz, HB), 3.07 (d, 1H, J = 4.1 Hz, HC), 2.99 (t, 1H, J = 5.0 Hz, HD),
2.41 (d, 1H, J = 10.8 Hz, HG), 2.0–2.02 (m, 1H, HF);13C NMR (cdcl3, 75 mhz) δ/ppm: 144.6 (s), 143.2 (s),
141.2 (s), 133.2 (d), 129.3 (d), 128.2 (2d), 127.3 (2d), 126.4 (d), 125.3 (d), 122.1 (d), 54.1 (d), 52.5 (d), 45.8 (d),
43.2 (t), 40.1 (d), 34.9 (t); MS m/z (%, fragment) (EI): 248; HRMS (m/z) for C18H16O: [M + H]+calcd =
249.1201, [M + H]+measured = 249.1190.
(2R,7R,8S,8as)-8-(4- ethoxyphenyl)-1a,7,8,8a-tetrahydro-2H-2,7-methanobenzo[4,5]cyclohepta[1,2-b]
oxirene (endo-39): Yield 50%; Rf (petroleum ether): 0.13; 1H NMR (CDCl3, 600 MHz) δ/ppm: 7.29 (d, 1H,
J = 7.3 Hz, Ar), 7.16 (t, 1H, J = 7.2 Hz, Ar), 6.95 (t, 1H, J = 7.2 Hz, Ar), 6.75 (d, 2H, J = 8.3 Hz, Ar),
6.61 (d, 2H, J = 8.3 Hz, Ar), 6.32 (d, 1H, J = 7.3 Hz, Ar), 3.79 (s, 3H, OCH3), 3.48 (d, 1H, J = 5.0 Hz, HE),
3.44 (t, 1H, J = 4.0 Hz, HA), 3.36 (t, 1H, J = 3.8 Hz, HB), 3.00 (d, 1H, J = 4.0 Hz, HC), 2.95 (t, 1H,
J = 5.0 Hz, HD), 2.38 (d, 1H, J = 10.8 Hz, HG), 2.05–2.00 (m, 1H, HF); 13C NMR (CDCl3, 150 MHz)
δ/ppm: 152.5 (s), 142.9 (s), 135.9 (s), 133.8 (s), 129.6 (2d), 126.8 (d), 126.7 (d), 125.8 (d), 122.5 (d),
113.8 (2d), 55.2 (d), 54.2 (d), 53.2 (q), 44.8 (d), 42.9 (t), 40.6 (d), 35.3 (d);MS m/z (%, fragment) (EI): 278;
HRMS (m/z) for C19H16O2: [M + H]+calcd = 279.1306, [M + H]+measured = 279.1325.
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3.6. Epoxide Ring Opening
To a solution of starting epoxide (0.8g) in THF, lithium aluminum hydride (2.5 eq) was added.
The reaction mixture was stirred at 76 ◦C during 24 h. After the reaction was complete, NaHCO3 was
added and pH was adjusted to 7. The water layer was washed twice with diethyl ether. Organic layers
were dried over MgSO4, filtered and evaporated to obtain crude material. Crude material was purified
on column chromatography using petroleum ether/dichloromethane as eluent.
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(6S)-6-Phenyl-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]anulen-7-ol (endo-40): Yield 40%; Rf 
(petroleum ether/ dichloromethane 40%): 0.20; 1H NMR (CDCl3, 600 MHz) /ppm 8.00–7.30 (m, 4H, 
Ar), 6.93–6.20 (m, 5H, Ar), 4.13 (m, 1H, HB) 3.40 (dd, 1H, J = 12.7, 4.7 Hz, HA/A1/E) 3.20 (t, 1H, J = 4.5 Hz, 
HA/A1/E), 3.14 (d, 1H, J = 4.5 Hz, HA/A1/E), 2.56 (d, 1H, J = 10.8 Hz, HG), 2.35 (s, 1H, OH), 2.25–2.20 (m, 
1H, HF) 1.63 (d, 1H, J = 4.8 Hz, HC/D), 1.60 (d, 1H, J = 4.8 Hz, HC/D); 13C NMR (CDCl3, 150 MHz) /ppm: 
143.8 (s), 142.3 (s), 133.9 (s), 129.3 (d), 128.9 (d), 127.6 (d), 127.2 (2d), 126.5 (d), 124.3 (2d), 122.1 (d), 
(6S)-6-Phenyl-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]anulen-7-ol (endo-40): Yield 40%; Rf (petroleum
ether/ dichloromethane 40%): 0.20; 1H NMR (CDCl3, 600 MHz) δ/ppm 8.00–7.30 ( , 4H, Ar), 6.93–6.20
(m, 5H, Ar), 4.13 (m, 1H, HB) 3.40 (dd, 1 , J = 12.7, 4.7 z, HA/A1/E) 3.20 (t, 1H, J = 4.5 Hz, A/A1/E), 3.14
(d, 1H, J = 4.5 Hz, A/A1/E), 2.56 (d, 1H, J = 10.8 Hz, HG), 2.35 (s, 1H, OH), 2.25–2.20 (m, 1 , HF) 1.63 (d, 1H,
J = 4.8 Hz, HC/D), 1.60 (d, 1 , J = 4.8 Hz, HC/D); 13C NMR (CD l3, 150 MHz) δ/ppm: 143.8 (s), 142.3 (s),
133.9 (s), 129.3 (d), 128.9 (d), 127.6 (d), 127.2 (2d), 126.5 (d), 124.3 (2d), 122.1 (d), 68.1 (d), 63.9 (t), 47.9 (d),
47.0 (d), 41.5 (d), 38.7 (t);MS m/z (%, fragment) (EI): 250; HRMS (m/z) for C18H18O: [M + H]+calcd = 251.1357,
[M + H]+measured = 251.1349.
(5R,6S,9S)-6-(4-methoxyphenyl)-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]anulen-7-ol (endo-41): Yield
35%; Rf (petroleum ether/ dichloromethane): 0.20; 1H NMR (CDCl3, 600 MHz) δ/ppm 7.85–7.32
(m, 3H, Ar), 6.98–6.24 (m, 5H, Ar), 4.31–4.28 (m, 1H, HB) 3.79 (s, 1H, OCH3) 3.65–3.63 (m, 1H,
HA/A1/E) 3.44 (t, 1H, J = 4.4 Hz, HA/A1/E), 3.36 (t, 1H, J = 3.8 Hz, HA/A1/E), 3.01 (dd, 1H, J = 4.0,
1.4 Hz, HC/D), 2.96 (t, 1H, J = 5.2 Hz, HC/D) 2.38 (d, 1H, J = 11,0 Hz, HG), 2.27 (s, 1H, OH), 2.05–2.00
(m, 1H, HF); MS m/z (%, fragment) (EI): 280; HRMS (m/z) for C19H20O2: [M + H]+calcd = 281.1463,
[M + H]+measured = 281.1609.
3.7. Synthesis of Ethers from Alcohols
Alcohol obtained after epoxide cleavage (0.05 g) was dissolved in acetone (2 mL), K2CO3 (1.5 eq)
and corresponding alkyl bromides (1.1 eq) were added. The reaction mixture was stirred over 24 h at
56 ◦C. After the reaction was complete, water and diethylether were added. The organic layer was
dried over MgSO4, filtered and evaporated to obtain a crude product. The crude material was purified
on column chromatography using petroleum ether and dichloromethane as eluents.
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68.1 (d), 63.9 (t), 47.9 (d), 47.0 (d), 41.5 (d), 38.7 (t);MS m/z (%, fragment) (EI): 250; HRMS (m/z) for 
C18H18O: [M + H]+calcd = 251.1357, [M + H]+measured = 251.1349. 
(5R,6S,9S)-6-(4-methoxyphenyl)-6,7,8,9-tetrahydro-5 -5,9-methanobenzo[7]anulen-7-ol (endo-41): 
Yield 35%; Rf (petroleum ether/ dichloromethane): 0.20; 1  NMR (CDCl3, 600 MHz) /ppm 7.85–7.32 
(m, 3H, Ar), 6.98–6.24 (m, 5H, Ar), 4.31–4.28 (m, 1H, B) 3.79 (s, 1H, OCH3) 3.65–3.63 (m, 1 , HA/A1/E) 
3. 4 (t, 1H, J = 4.4 Hz, HA/A1/E), 3.36 (t, 1H, J = 3.8 Hz, HA/A1/E), 3.01 (dd, 1H, J = 4.0, 1.4 Hz, C/D), 2,96 (t, 
1H, J = 5,2 Hz, HC/D) 2,38 (d, 1H, J = 11,0 Hz, HG), 2,27 (s, 1H, OH), 2,05–2,00 (m, 1H, HF); MS m/z (%, 
fragment) (EI): 280; HRMS (m/z) for C19H20O2: [M + H]+calcd = 281.1463, [M + H]+measured = 281.1609. 
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(5R,6S,9S)-7-Ethoxy-6-phenyl-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]annulene (endo-42): Yield 
20%; Rf (petroleum ether/dichloromethane): 0.52; 1H NMR (CDCl3, 600 MHz) /ppm: 7.72 (d, 1H, J = 
7.3 Hz), 7.33–7.19 (m, 4H), 7.05–7.01(m, 2H), 7.14 (t, 1H, J = 7.4 Hz), 6.74 (t, 1H, J = 7.3 Hz), 4.16–4.11 
(m, 2H), 3.35–3.30 (m, 2H), 3.01 (d, 1H, J = 11.0 Hz), 2.18–2.13 (m, 1H), 2.09–2.07 (m, 1H), 1.89 (dd, 2H, 
J = 15.2, 4.5 Hz), 1.76–1.73 (t, 3H, J = 6.9 Hz, CH3); MS m/z (%, fragment) (EI): 280 (100). 
(5R,6S,9S)-6-Phenyl-7-propoxy-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]annulene (endo-43): Yield 
40%; Rf (petroleum ether/dichloromethane): 0.57; 1H NMR (CDCl3, 600 MHz) /ppm: 7.42 (t, 1H, J = 
7.5 Hz), 7.33 (d,1H, J = 7.1 Hz), 7.28 (d, 2H, J = 7.9 Hz), 7.23 (t, 2H, J = 7.5 Hz), 7.14 (t, 2H, J = 7.9 Hz), 
6.48 (d, 1H, J = 7.1 Hz), 4.68–4.63 (m, 2H), 4.19–4.14 (m, 2H), 3.31 (m, 2H), 3.03 (d, 1H, J = 11.0 Hz), 
2.18–2.13 (m, 1H), 2.09–2.07 (m, 1H), 1.89 (dd, 2H, J = 15.2; 4.5 Hz), 1.71 (d, 1H, J = 10.5 Hz), 1.28 (t, 
3H, J = 6.9 Hz, CH3); 13C NMR (CDCl3, 150 MHz) /ppm: 145.3 (s), 145.1 (s), 144.3 (s), 127.6 (d), 127.5 
(2d), 126.9 (d), 126.6 (2d), 125.7 (d), 124.5 (d), 122.5 (d), 68.8 (d), 53.3 (d), 47.5 (t), 46.8 (d), 39.7 (t), 36.9 
(t), 33.8 (t), 32.4 (d), 25.5 (q);MS m/z (%, fragment) (EI): 292 (100); HRMS (m/z) for C21H24O: [M + H]+calcd 
= 293.1827, [M + H]+measured = 293.1846. 
(5R,6S,9S)-7-Isopropoxy-6-phenyl-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]annulene (endo-44): 
Yield 50%; Rf (petroleum ether/dichloromethane) = 0.55; 1H NMR (CDCl3, 600 MHz) /ppm: 7.33 (t, 
1H, J = 7.0 Hz), 7.30–7.28 (m, 1H), 7.23 (t, 3H, J = 7.7 Hz), 7.14 (d, 1H, J = 7.3 Hz), 6.98 (d, 1H, J = 7.3 
Hz), 6.47 (d, 2H, J = 7.7 Hz), 4.19–4.14 (m, 1H), 3.50–3.46 (m, 1H, isopropyl-CH), 3.24–3.20 (m, 2H), 
2.98 (d, 1H, J = 11.1 Hz), 2.17–2.12 (m, 1H), 2.06–2.01 (m, 1H), 1.81 (dd, 1H, J = 15.0; 4.3 Hz), 1.67 (d, 
1H, J = 15.0 Hz), 1.29 (broad s, 6H);13C NMR (CDCl3, 150 MHz) /ppm: 145.4 (s), 145.2 (s), 144.3 (s), 
127.5 (2d), 126.9 (d), 126.8 (d), 126.5 (2d), 125.7 (d), 124.8 (d), 122.5 (d), 68.8 (d), 53.3 (d), 46.8 (d), 43.2 
(d), 39.7 (d), 36.9 (t), 34.1 (t), 27.4 (2q); MS m/z (%, fragment) (EI): 292 (100); HRMS (m/z) for C21H24O: 
[M + H]+calcd = 293.1827, [M + H]+measured = 293.1814. 
3-(((5R,6S,9S)-6-Phenyl-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]annulen-7-il)oxy)propan-1-ol 
(endo-45): Yield 45%; Rf (petroleum ether/dichloromethane): 0.50; 1H NMR (CDCl3, 600 MHz) /ppm 
7.28 (d, 1H, J = 7.3 Hz, Ar), 7.21–7.18 (m, 3H, Ar), 7.15 (t, 1H, J = 7.3 Hz, Ar), 6.92 (t, 1H, J = 7.3 Hz, Ar), 
6.69 (dd, 2H, J = 6.6; 3.3 Hz, Ar), 6.24 (d, 1H, J = 7.3 Hz, Ar), 3.57–3.44 (m, 4H), 3.52 (d, 1H, J = 4.8 Hz, 
HB), 3.44 (t, 1H, J = 4.2 Hz, HE), 3.37 (t, 1H, J = 3.8 Hz, HA/A1), 3.05 (dd, 1H, J = 4.2 Hz, HC), 2.98 (t, 1H, 
(5R,6S,9S)-7-Ethoxy-6-phenyl-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]annulene (endo-42): Yield
20%; Rf (petroleum ether/dichloromethane): 0.52; 1H NMR (CDCl3, 600 M z) δ/ppm: 7.72 (d, 1H,
J = 7.3 Hz), 7.3 –7.19 (m, 4H), 7.05–7.01(m, 2H), 7.14 (t, 1H, J = 7.4 Hz), 6.74 (t, 1H, J = 7.3 Hz), 4.16–4.11
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(m, 2H), 3.35–3.30 (m, 2H), 3.01 (d, 1H, J = 11.0 Hz), 2.18–2.13 (m, 1H), 2.09–2.07 (m, 1H), 1.89 (dd, 2H,
J = 15.2, 4.5 Hz), 1.76–1.73 (t, 3H, J = 6.9 Hz, CH3); MS m/z (%, fragment) (EI): 280 (100).
(5R,6S,9S)-6-Phenyl-7-propoxy-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]annulene (endo-43): Yield
40%; Rf (petroleum ether/dichloromethane): 0.57; 1H NMR (CDCl3, 600 MHz) δ/ppm: 7.42 (t, 1H,
J = 7.5 Hz), 7.33 (d,1H, J = 7.1 Hz), 7.28 (d, 2H, J = 7.9 Hz), 7.23 (t, 2H, J = 7.5 Hz), 7.14 (t, 2H, J = 7.9 Hz),
6.48 (d, 1H, J = 7.1 Hz), 4.68–4.63 (m, 2H), 4.19–4.14 (m, 2H), 3.31 (m, 2H), 3.03 (d, 1H, J = 11.0 Hz),
2.18–2.13 (m, 1H), 2.09–2.07 (m, 1H), 1.89 (dd, 2H, J = 15.2; 4.5 Hz), 1.71 (d, 1H, J = 10.5 Hz), 1.28 (t, 3H,
J = 6.9 Hz, CH3); 13C NMR (CDCl3, 150 MHz) δ/ppm: 145.3 (s), 145.1 (s), 144.3 (s), 127.6 (d), 127.5 (2d),
126.9 (d), 126.6 (2d), 125.7 (d), 124.5 (d), 122.5 (d), 68.8 (d), 53.3 (d), 47.5 (t), 46.8 (d), 39.7 (t), 36.9 (t),
33.8 (t), 32.4 (d), 25.5 (q);MS m/z (%, fragment) (EI): 292 (100); HRMS (m/z) for C21H24O: [M + H]+calcd
= 293.1827, [M + H]+measured = 293.1846.
(5R,6S,9S)-7-Isopropoxy-6-phenyl-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]annulene (endo-44): Yield
50%; Rf (petroleum ether/dichloromethane) = 0.55; 1H NMR (CDCl3, 600 MHz) δ/ppm: 7.33 (t, 1H,
J = 7.0 Hz), 7.30–7.28 (m, 1H), 7.23 (t, 3H, J = 7.7 Hz), 7.14 (d, 1H, J = 7.3 Hz), 6.98 (d, 1H, J = 7.3 Hz),
6.47 (d, 2H, J = 7.7 Hz), 4.19–4.14 (m, 1H), 3.50–3.46 (m, 1H, isopropyl-CH), 3.24–3.20 (m, 2H), 2.98
(d, 1H, J = 11.1 Hz), 2.17–2.12 (m, 1H), 2.06–2.01 (m, 1H), 1.81 (dd, 1H, J = 15.0; 4.3 Hz), 1.67 (d, 1H,
J = 15.0 Hz), 1.29 (broad s, 6H);13C NMR (CDCl3, 150 MHz) δ /ppm: 145.4 (s), 145.2 (s), 144.3 (s),
127.5 (2d), 126.9 (d), 126.8 (d), 126.5 (2d), 125.7 (d), 124.8 (d), 122.5 (d), 68.8 (d), 53.3 (d), 46.8 (d), 43.2 (d),
39.7 (d), 36.9 (t), 34.1 (t), 27.4 (2q); MS m/z (%, fragment) (EI): 292 (100); HRMS (m/z) for C21H24O:
[M + H]+calcd = 293.1827, [M + H]+measured = 293.1814.
3-(((5R,6S,9S)-6-Phenyl-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]annulen-7-il)oxy)propan-1-ol
(endo-45): Yield 45%; Rf (petroleum ether/dichloromethane): 0.50; 1H NMR (CDCl3, 600 MHz)
δ/ppm 7.28 (d, 1H, J = 7.3 Hz, Ar), 7.21–7.18 (m, 3H, Ar), 7.15 (t, 1H, J = 7.3 Hz, Ar), 6.92 (t, 1H,
J = 7.3 Hz, Ar), 6.69 (dd, 2H, J = 6.6; 3.3 Hz, Ar), 6.24 (d, 1H, J = 7.3 Hz, Ar), 3.57–3.44 (m, 4H), 3.52 (d,
1H, J = 4.8 Hz, HB), 3.44 (t, 1H, J = 4.2 Hz, HE), 3.37 (t, 1H, J = 3.8 Hz, HA/A1), 3.05 (dd, 1H, J = 4.2 Hz,
HC), 2.98 (t, 1H, J = 5.1 Hz, HD), 2.40 (d, 1H, J = 10.7 Hz, HG), 2.11–2.06 (m, 1H, HA/A1), 2.06–2.01
(m, 1H, HF), 1.42 (s, 1H, OH), 1.24 (broad s, 2H); 13C NMR (CDCl3, 150 MHz) δ /ppm: 145.2 (s),
143.5 (s), 141.7 (s), 128.6 (2d), 127.7 (2d), 126.8 (d), 126.3 (d), 126.0 (d), 125.7 (d), 122.5 (d), 68.2 (d),
54.5 (t), 52.9 (d), 50.4 (t), 45.9 (d), 43.7 (d), 40.6 (t), 39.9 (t), 35.5 (t); MS m/z (%, fragment) (EI): 308; HRMS
(m/z) for C21H24O2: [M + H]+calcd = 309.1776, [M + H]+measured = 309.4140.
Molecules 2020, 25, x FOR PEER REVIEW 20 of 25 
 
J = 5.1 Hz, HD), 2.40 (d, 1H, J = 10.7 Hz, HG), 2.11–2.06 (m  1H, HA/A1), 2.06–2.0  (m, 1H, HF), 1.4  (s, 
1H, OH), 1.24 (broad s, 2H); 13C NMR (CDCl3, 150 MHz) /ppm: 145.2 (s), 143.5 (s), 141.7 (s), 128.6 
(2d), 127.7 (2d), 126.8 (d), 126.3 (d), 126.0 (d), 125.7 (d), 122.5 (d), 68.2 ( ), 54.5 (t), 52.9 (d), 50.4 (t), 45.9 
(d), 43.7 (d), 40.6 (t), 39.9 (t), 35.5 (t); MS m/z (%, fragment) EI): 308; HRMS (m/z) for C21H24O2: [  + 
H]+calcd = 309.1776, [M + H]+measured = 309.4 40. 
 
(5R,6S,9S)-7-Ethoxy-6-(4-methoxyphenyl)-6,7,8,9-tetrahydro-5H-5,9-methanobenzo-[7]annulene 
(endo–46): Yield 20%; Rf (petroleum ether/dichloromethane): 0.67; 1H NMR (CDCl3, 600 MHz) /ppm 
7.30 (d, 1H, J = 7.5 Hz), 7.17 (t, 1H, J = 7.5 Hz), 6.96 (t, 1H, J = 7.5 Hz), 6.76 (d, 2H, J = 8.6 Hz), 6.62 (d, 
2H, J = 8.6 Hz), 6.33 (d, 1H, J = 7.5 Hz), 3.79 (s, 3H), 3.51–3.48 (m, 2H), 3.45 (t, 1H, J = 4.8 Hz), 3.38 (t, 
1H, J = 4.2 Hz), 3.03 (d, 1H, J = 4.2 Hz), 2.97 (t, 1H, J = 4.8 Hz), 2.38-2.33 (m, 2H), 2.39 (d, 1H, J = 10.8 
Hz), 2.06–2.01 (m, 1H), 1.27 (s, 3H); MS m/z (%, fragment) (EI): 308 (100). 
(5R,6S,9S)-6-(4-Methoxyphenyl)-7-propoxy-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]annulene 
(endo-47): Yield 35%; Rf (petroleum ether/dichloromethane):0.57; 1H NMR (CDCl3, 600 MHz) /ppm 
7.21 (d, 1H, J = 7.3 Hz), 7.08 (t, 1H, J = 7.4 Hz), 6.87 (t, 1H, J = 7.4 Hz), 6.67 (d, 2H, J = 8.6 Hz), 6.53 (d, 
2H, J = 8.6 Hz), 6.24 (d, 1H, J = 7.3 Hz), 3.70 (s, 3H, OCH3), 3.51 (q, 2H, J = 6.6 Hz), 3.40 (t, 1H, J = 4.8 
Hz), 3.36 (t, 1H, J = 4.3 Hz), 2.93 (d, 1H, J = 3.7 Hz), 2.87 (t, 1H, J = 4.9 Hz), 2.39–2.35 (m, 4H), 2.30 (d, 
1H, J = 10.8 Hz), 1.99–1.96 (m, 1H), 1.18 (broad s, 3H); 13C NMR (CDCl3, 150 MHz) /ppm: 157.5 (s), 
144.5 (s), 143.2 (s), 133.5 (s), 129.2 (d), 127.1 (d), 126.4 (2d), 126.2 (d), 122.1 (2d), 112.6 (d), 54.7 (d), 54.0 
(d), 52.7 (d), 45.5 (d), 42.4 (d), 40.1 (d), 34.7 (t), 30.4 (q); MS m/z (%, fragment) (EI): 322; HRMS (m/z) 
for C22H26O2: [M + H]+calcd = 323.1932, [M + H]+measured = 323.4406. 
3-(((5R,6S,9S)-6-(4-Methoxyphenyl)-6,7,8,9-tetrahydro-5H-5,9-methanobenzo-[7]annulen-7-
il)oxy)propan-1-ol (endo-48): Yield 15%; Rf (petroleum ether/dichloromethane): 0.64; 1H NMR (CDCl3, 
600 MHz) /ppm 6.95 (d, 1H, J = 7.4 Hz), 6.82 (t, 1H, J = 7.3 Hz), 6.75 (t, 1H, J = 7.3 Hz), 6,71 (d, 2H, J = 
8,5 Hz, Ar), 6,63 (d, 1H, J = 7,4 Hz, Ar), 6,46 (d, 2H, J = 8,6 Hz, Ar), 4,20–4,16 (m, 1H), 3,72–3,66 (m, 
4H, CH2CH2), 3,64 (s, 3H, OCH3), 3,53 (t, 1H, J = 4,8 Hz), 3,31–3,25 (m, 1H), 2,96 (s, 1H, OH), 2,57 (dt, 
1H, J = 14,3; 3,4 Hz), 2,44–2,39 (m, 1H), 2,28–2,23 (m, 1H), 2,04–1,97 (m, 2H), 1,17 (broad s, 2H); MS 
m/z (%, fragment) (EI): 338; HRMS (m/z) for C22H26O3: [M + H]+calcd = 339.1881, [M + H]+measured = 
339.4404. 
3.8. Friedel-Crafts Acylation 
To the solution of compound 49 [41] (100 mg, 0.510 mol) in dichloromethane (2 mL), AlCl3 (68 
mg, 0.510 mol) and different carbonyl chlorides (1.1 eq) were added. The reaction was performed in 
a sealed tube and left overnight at room temperature. After removal of the solvent, the residue crude 
product was purified by repeated column chromatography using petroleum ether/dichloromethane 
mixture as eluent. All of the obtained compounds 50–57 were isolated in the first fractions.  
 
(5R,6S,9S)-7-Ethoxy-6-(4-methoxyphenyl)-6,7,8,9-tetrahydro-5H-5,9-methanobenzo-[7]annulene
(endo–46): Yield 20%; Rf (petroleum ether/dichloromethane): 0.67; 1H NMR (CDCl3, 600 MHz) δ/ppm
7.30 (d, 1H, J = 7.5 Hz), 7.17 (t, 1H, J = 7.5 Hz), 6.96 (t, 1H, J = 7.5 Hz), 6.76 (d, 2H, J = 8.6 Hz), 6.62
(d, 2H, J = 8.6 Hz), 6.33 (d, 1H, J = 7.5 Hz), 3.79 (s, 3H), 3.51–3.48 (m, 2H), 3.45 (t, 1H, J = 4.8 Hz),
3.38 (t, 1H, J = 4.2 Hz), 3.03 (d, 1H, J = 4.2 Hz), 2.97 (t, 1H, J = 4.8 Hz), 2.38-2.33 (m, 2H), 2.39 (d, 1H,
J = 10.8 Hz), 2.06–2.01 (m, 1H), 1.27 (s, 3H); MS m/z (%, fragment) (EI): 308 (100).
(5R,6S,9S)-6-(4-Methoxyphenyl)-7-propoxy-6,7,8,9-tetrahydro-5H-5,9-methanobenzo[7]annulene
(endo-47): Yield 35%; Rf (petroleum ether/dichloromethane):0.57; 1H NMR (CDCl3, 600 MHz) δ/ppm
7.21 (d, 1H, J = 7.3 Hz), 7.08 (t, 1H, J = 7.4 Hz), 6.87 (t, 1H, J = 7.4 Hz), 6.67 (d, 2H, J = 8.6 Hz), 6.53
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(d, 2H, J = 8.6 Hz), 6.24 (d, 1H, J = 7.3 Hz), 3.70 (s, 3H, OCH3), 3.51 (q, 2H, J = 6.6 Hz), 3.40 (t, 1H,
J = 4.8 Hz), 3.36 (t, 1H, J = 4.3 Hz), 2.93 (d, 1H, J = 3.7 Hz), 2.87 (t, 1H, J = 4.9 Hz), 2.39–2.35 (m, 4H),
2.30 (d, 1H, J = 10.8 Hz), 1.99–1.96 (m, 1H), 1.18 (broad s, 3H); 13C NMR (CDCl3, 150 MHz) δ/ppm:
157.5 (s), 144.5 (s), 143.2 (s), 133.5 (s), 129.2 (d), 127.1 (d), 126.4 (2d), 126.2 (d), 122.1 (2d), 112.6 (d),
54.7 (d), 54.0 (d), 52.7 (d), 45.5 (d), 42.4 (d), 40.1 (d), 34.7 (t), 30.4 (q); MS m/z (%, fragment) (EI): 322;
HRMS (m/z) for C22H26O2: [M + H]+calcd = 323.1932, [M + H]+measured = 323.4406.
3-(((5R,6S,9S)-6-(4-Methoxyphenyl)-6,7,8,9-tetrahydro-5H-5,9-methanobenzo-[7]annulen-7-il)oxy)propan
-1-ol (endo-48): Yield 15%; Rf (petroleum ether/dichloromethane): 0.64; 1H NMR (CDCl3, 600 MHz)
δ/ppm 6.95 (d, 1H, J = 7.4 Hz), 6.82 (t, 1H, J = 7.3 Hz), 6.75 (t, 1H, J = 7.3 Hz), 6.71 (d, 2H, J = 8.5 Hz, Ar),
6.63 (d, 1H, J = 7.4 Hz, Ar), 6.46 (d, 2H, J = 8,6 Hz, Ar), 4.20–4.16 (m, 1H), 3.72–3.66 (m, 4H, CH2CH2),
3.64 (s, 3H, OCH3), 3.53 (t, 1H, J = 4.8 Hz), 3.31–3.25 (m, 1H), 2.96 (s, 1H, OH), 2.57 (dt, 1H, J = 14.3;
3.4 Hz), 2.44–2.39 (m, 1H), 2.28–2.23 (m, 1H), 2.04–1.97 (m, 2H), 1.17 (broad s, 2H); MS m/z (%, fragment)
(EI): 338; HRMS (m/z) for C22H26O3: [M + H]+calcd = 339.1881, [M + H]+measured = 339.4404.
3.8. Friedel-Crafts Acylation
To the solution of compound 49 [41] (100 mg, 0.510 mol) in dichloromethane (2 mL), AlCl3 (68 mg,
0.510 mol) and different carbonyl chlorides (1.1 eq) were added. The reaction was performed in a
sealed tube and left overnight at room temperature. After removal of the solvent, the residue crude
product was purified by repeated column chromatography using petroleum ether/dichloromethane
mixture as eluent. All of the obtained compounds 50–57 were isolated in the first fractions.
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J = 5.1 Hz, HD), 2.40 (d, 1H, J = 10.7 Hz, HG), 2.11–2.06 (m, 1H, HA/A1), 2.06–2.01 (m, 1H, HF), 1.42 (s, 
1H, OH), 1.24 (broad s, 2H); 13C NMR (CDCl3, 150 MHz) /ppm: 145.2 (s), 143.5 (s), 141.7 (s), 128.6 
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(endo-47): Yield 35%; Rf (petroleum ether/dichloromethane):0.57; 1H NMR (CDCl3, 600 MHz) /ppm 
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2H, J = 8.6 Hz), 6.24 (d, 1H, J = 7.3 Hz), 3.70 (s, 3H, OCH3), 3.51 (q, 2H, J = 6.6 Hz), 3.40 (t, 1H, J = 4.8 
Hz), 3.36 (t, 1H, J = 4.3 Hz), 2.93 (d, 1H, J = 3.7 Hz), 2.87 (t, 1 , J = 4.9 Hz), 2.39–2.35 (m, 4H), 2.30 (d, 
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(d), 2.7 (d), 45.5 (d), 42.4 (d), 40.1 (d), 34.7 (t), 30.4 (q); MS m/z (%, fragment) (EI): 322; HRMS (m/z) 
for C22H26O2: [M + H]+calcd = 323.1932, [M + H]+measured = 323.4406. 
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il)oxy)propan-1-ol (endo-48): Yield 15%; Rf (petroleum ether/dichloromethane): 0.64; 1H NMR (CDCl3, 
600 MHz) /ppm 6.95 (d, 1H, J = 7.4 Hz), 6.82 (t, 1H, J = 7.3 Hz), 6.75 (t, 1H, J = 7.3 Hz), 6,71 (d, 2H, J = 
8,5 Hz, Ar), 6,63 (d, 1H, J = 7,4 Hz, Ar), 6,46 (d, 2H, J = 8,6 Hz, Ar), 4,20–4,16 (m, 1 ), 3,72–3,66 (m, 
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(Z)-4-((5R,9R)-7-Hydroxy-5,7,8,9-tetrahydro-6H-5,9-methanobenzo[7]annulen-6-ilydene)butan-2-one
(50): 16 mg (13%); yellow oil; Rf (dichloromethane): 0.5; 1H NMR (CDCl3, 600 MHz) δ/ppm: 7.54
(d, 1H, J = 7.7 Hz, HAr), 7.29 (t, 1H, J = 7.7 Hz, HAr), 7.14 (t, 1H, J = 7.7 Hz, HAr), 7.10 (d, 1H,
J = 7.7 Hz, HAr), 6.79 (m, 1H), 3.83 (m, 1H), 3.62 (d, 1H, J = 3.6 Hz), 3.24 (t, 1H, J = 6.6 Hz), 3.01 (d, 1H,
J = 4.6 Hz), 2.45 (m, 1H), 2.28 (s, 1H, -OH), 2.31 (d, 1H, J = 10.7 Hz,), 2.29 (m, 2H), 2.06–2.02 (m, 1H),
1.95 (s, 3H); MS m/z (%, fragment) (EI): 242 (100); HRMS (m/z) for C16H18O2: [M + H]+calcd = 243.1306,
[M + H]+measured = 243.3129.
(5R,9R,Z)-6-((Z)-3-Hydroxybut-2-ene-1-ilydene)-6,7,8,9-tetrahydro-5H-5,9-methano-benzo[7]annulen-
7-ol (51): 30 mg (30%); yellow oil; Rf (dichloromethane/petroleum ether 70%): 0.10; 1H NMR (CDCl3,
600 MHz) δ/ppm: 7.30 (d, 1H, J = 7.5 Hz, HAr), 7.16 (t, 1H, J = 7.5 Hz, HAr), 6.93 (t, 1H, J = 7.5 Hz, HAr),
6.70 (m, 2H), 6.26 (d, J = 7.3 Hz, 1H), 3.53 (d, 1H, J = 5.1 Hz), 3.45 (t, 1H, J = 4.4 Hz), 3.38 (t, 1H,
J = 3.9 Hz), 3.06 (dd, 1H, J = 4.0; 1.5 Hz), 2.99 (t, 1H, J = 5.1 Hz), 2.41 (d, 1H, J = 10.9 Hz), 2.10
(s, 1H, OH), 2.06–2.02 (m, 1H), 1.53 (s, 3H); MS m/z (%, fragment) (EI): 242 (100); HRMS (m/z) for
C16H18O2: [M + H]+calcd = 243.1306, [M + H]+measured = 243.3131.
(E)-1-((5S,9R)-5,9-Dihydro-6H-5,9-methanobenzo[7]annulen-6-ilydene)hexa-2,3-dione (52): 21 mg (15%);
yellow oil; Rf (dichloromethane): 0.40; 1H NMR (CDCl3, 600 MHz) δ/ppm: 8.07 (d, 1H, J = 7.9 Hz, HAr),
7.83 (d, 1H, J = 7.9 Hz, HAr), 7.13–7.09 (m, 2H), 6.26 (dd, 1H, J = 6.8; 1.8 Hz), 6.02 (d, 1H, J = 9.6 Hz),
5.91 (d, 1H, J = 9.6 Hz), 4.25–4.19 (m, 2H), 3.55–3.51 (m, 2H), 2.71 (d, 1H, J = 11.2 Hz), 2.35–2.31
(m, 2H), 2.04–2.01 (m, 1H), 1.63 (s, 3H); MS m/z (%, fragment) (EI): 266 (100); HRMS (m/z) for C18H18O2:
[M + H]+calcd = 267.1306, [M + H]+measured = 267.3343.
(Z)-1-((5R,9R)-7-Hydroxy-5,9-dihydro-6H-5,9-methanobenzo[7]annulen-6-ilydene)-pentan-3-one (53):
76 mg (59%); yellow oil; Rf (dichloromethane): 0.29; 1H NMR (CDCl3, 600 MHz) δ/ppm: 8.04 (d, 1H,
J = 8.5 Hz, HAr), 7.93 (d, 1H, J = 9.1 Hz, HAr), 7.50 (t, 1H, J = 7.7 Hz, HAr), 7.16 (m, 1H, HAr), 6.30
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(dd, 1H, J = 3.1; 1.9 Hz), 6.10 (d, 1H, J = 3.1 Hz), 4.59 (d, 1H, J = 6.3 Hz), 4.42 (d, 1H, J = 5.6 Hz), 4.33
(s, 1H, OH), 4.10–4.07 (m, 2H), 2.28 (d, 1H, J = 11.5 Hz), 1.93–1.83 (m, 1H) 1.80–1.69 (m, 2H), 1.00 (t, 3H,
J = 5.4 Hz); MS m/z (%, fragment) (EI): 254 (100); HRMS (m/z) for C17H18O2: [M + H]+calcd = 255.1306,
[M + H]+measured = 255.3236.
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7-ol (51): 30 mg (30%); yellow oil; Rf (dichloromethane/ petroleum ether 70%): 0.10; 1H NMR (CDCl3, 
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= 243.1306, [M+H]+measured = 243.3131. 
(E)-1-((5S,9R)-5,9-Dihydro-6H-5,9-methanobenzo[7]annulen-6-ilydene)hexa-2,3-dione (52): 21 mg 
(15%); yellow oil; Rf (dichloromethane): 0.40; 1H NMR (CDCl3, 600 MHz) /ppm: 8.07 (d, 1H, J= 7.9 
Hz, HAr), 7.83 (d, 1H, J = 7.9 Hz, HAr), 7.13–7.09 (m, 2H), 6.26 (dd, 1H, J = 6.8; 1.8 Hz), 6.02 (d, 1H, J = 
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2.31 (m, 2H), 2.04–2.01 (m, 1H), 1.63 (s, 3H); MS m/z (%, fragment) (EI): 266 (100); HRMS (m/z) for 
C18H18O2: [M + H]+calcd = 267.1306, [M + H]+measured = 267.3343. 
(Z)-1-((5R,9R)-7-Hydroxy-5,9-dihydro-6H-5,9-methanobenzo[7]annulen-6-ilydene)-pentan-3-one (53): 
76 mg (59%); yellow oil; Rf (dichloromethane): 0.29; 1H NMR (CDCl3, 600 MHz) /ppm: 8.04 (d, 1H, J 
= 8.5 Hz, HAr), 7.93 (d, 1H, J = 9.1 Hz, HAr), 7.50 (t, 1H, J = 7.7 Hz, HAr), 7.16 (m, 1H, HAr), 6.30 (dd, 1H, 
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= 255.3236. 
 
(9Z)-9-[(Z)-3-Hydroxypent-2-enilydene]tricyclo[6.3.1.02,7]dodeca-2(7),3,5-trien-10-ol (54): 8.9 mg 
(12%); yellow oil; Rf (dichloromethane/petroleum ether 20%): 0.73; 1H NMR (CDCl3, 600 MHz) /ppm: 
7.44–7.02 (m, 4H), 6,64 (m, 1H), 6.27 (d, 1H, J = 7.8 Hz), 3.63 (q, 2H, J = 6.8 Hz), 3.51 (d, 1H, J = 4.5 Hz), 
3.44 (t, 1H, J = 4.5 Hz), 3.37 (t, 1H, J = 4.5 Hz), 2.99 (dd, 1H, J = 3.0; 1.5 Hz), 2.95 (t, 1H, J = 4.5 Hz), 2.38 
(d, 1H, J = 10.6 Hz), 2.05-2.02 (m, 1H), 1.56 (t, 3H, J = 7.2 Hz); MS m/z (%, fragment) (EI): 256 (100). 
(Z)-3-((5R,9R)-7-Hydroxy-5,9-dyhidro-6H-5,9-methanobenzo[7]annulen-6-ilydene)-1-phenylpropan-1-
one (55): 29.4 mg (19%); colourless oil; Rf (dichloromethane): 0.38; 1H NMR (CDCl3, 600 MHz) δ/ppm: 
8.01 (d, 2H, J = 8.7 Hz, HAr), 7.90 (t, 2H, J = 8.9 Hz, HAr), 7.71 (d, 1H, J = 8.3 Hz, HAr), 7.68 (d, 1H, J = 9.2 
Hz, HAr), 7.50–7.43 (m, 3H, HAr), 6.30 (m, 1H), 6.10 (d, 1H, J = 3.3 Hz), 4.71 (s, 1H, OH), 4.58 (d, 1H, J = 
4.3 Hz), 4.39 (d, 1H, J = 4.9 Hz), 4.12 (t, 2H, J = 4.9 Hz), 2.40 (d, 1H, J = 10.5 Hz), 2.33–2.28 (m, 1H); MS 
m/z (%, fragment) (EI): 302 (100). 
(E)-5-Chloro-1-((5S,9R)-5,9-dyhdro-6H-5,9-methanobenzo[7]annulen-6-ilydene)penta-2,3-dione (56): 
7.5 mg (7.3%); colorless oil; Rf (dichloromethane): 0.42; 1H NMR (CDCl3, 600 MHz) /ppm: 8.01 (d, 
1H, J = 7.6 Hz, HAr), 7.13 (d, 1H, J = 7.6 Hz, HAr), 7.10–7.05 (m, 2H, HAr), 6.26 (dd, 1H, J = 6.5; 1.6 Hz), 
(9Z)-9-[(Z)-3-Hydroxypent-2-enilydene]tricyclo[6.3.1.02,7]dodeca-2(7),3,5-trien-10-ol (54): 8.9 mg (12%);
yellow oil; Rf (dichloromethane/petroleum ether 20%): 0.73; 1H NMR (CDCl3, 600 MHz) δ/ppm:
7.44–7.02 (m, 4H), 6,64 (m, 1H), 6.27 (d, 1H, J = 7.8 Hz), 3.63 (q, 2H, J = 6.8 Hz), 3.51 (d, 1H, J = 4.5 Hz),
3.44 (t, 1H, J = 4.5 Hz), 3.37 (t, 1H, J = 4.5 Hz), 2.99 (dd, 1H, J = 3.0; 1.5 Hz), 2.95 (t, 1H, J = 4.5 Hz), 2.38
(d, 1H, J = 10.6 Hz), 2.05-2.02 (m, 1H), 1.56 (t, 3H, J = 7.2 Hz); MS m/z (%, fragment) (EI): 256 (100).
(Z)-3-((5R,9R)-7-Hydroxy-5,9-dyhidro-6H-5,9-methanobenzo[7]annulen-6-ilydene)-1-phenylpropan-1-one
(55): 29.4 mg (19%); colourless oil; Rf (dichloromethane): 0.38; 1H NMR (CDCl3, 600 MHz) δ/ppm:
8.01 (d, 2H, J = 8.7 Hz, HAr), 7.90 (t, 2H, J = 8.9 Hz, HAr), 7.71 (d, 1H, J = 8.3 Hz, HAr), 7.68 (d, 1H,
J = 9.2 Hz, HAr), 7.50–7.43 (m, 3H, HAr), 6.30 (m, 1H), 6.10 (d, 1H, J = 3.3 Hz), 4.71 (s, 1H, OH), 4.58
(d, 1H, J = 4.3 Hz), 4.39 (d, 1H, J = 4.9 Hz), 4.12 (t, 2H, J = 4.9 Hz), 2.40 (d, 1H, J = 10.5 Hz), 2.33–2.28
(m, 1H); MS m/z (%, fragment) (EI): 302 (100).
(E)-5-Chloro-1-((5S,9R)-5,9-dyhdro-6H-5,9-methanobenzo[7]annulen-6-ilydene)penta-2,3-dione (56):
7.5 mg (7.3%); colorless oil; Rf (dichloromethane): 0.42; 1H NMR (CDCl3, 600 MHz) δ/ppm: 8.01 (d, 1H,
J = 7.6 Hz, HAr), 7.13 (d, 1H, J = 7.6 Hz, HAr), 7.10–7.05 (m, 2H, HAr), 6.26 (dd, 1H, J = 6.5; 1.6 Hz), 6.14
(d, 1H, J = 9.3 Hz), 5.98 (d, 1H, J = 9.3 Hz), 4.25–4.19 (m, 2H), 3.55 (m, 2H), 2.71 (d, 1H, J = 11.1 Hz),
2.33 (m, 2H), 2.07–2.03 (m, 1H); MS m/z (%, fragment) (EI): 286 (100), 288 (32).
(Z)-1-(2-Chlorophenyl)-3-((5R,9R)-7-hydroxy-5,9-dihydro-6H-5,9-methanobenzo-[7]annulen-6-ilydene)
propan-1-one (57): 9.5 mg (8%); colorless oil; Rf (dichloromethane): 0.40; 1H NMR (CDCl3, 600 MHz)
δ/ppm: 8.02 (d, 1H, J = 8.9 Hz, HAr), 7.90 (t, 2H, J = 9.2 Hz, HAr), 7.81 (d, 1H, J = 8.3 Hz, HAr), 7.70
(d, 1H, J = 9.2 Hz, HAr), 7.50–7.43 (m, 3H, HAr), 6.28 (dd, 1H, J = 3.2; 1.8 Hz), 6.08 (d, 1H, J = 3.1 Hz),
4.55 (d, 1H, J = 6.1 Hz), 4.21 (d, 1H, J = 5.7 Hz), 3.98 (t, 2H, J = 6.1 Hz), 3.18 (s, 1H, -OH), 2.03–1.99
(m, 2H); MS m/z (%, fragment) (EI): 336 (100), 338 (32).
3.9. Reversible Inhibition of Cholinesterases by Novel Compounds
Inhibition of novel compounds was evaluated for recombinant human AChE and BChE derived
from purified human plasma (a generous gift from Dr Florian Nachon, Département de Toxicologie et
Risques Chimiques, Institut de Recherche Biomédicale des Armées, Bretigny-sur-Orge, France). The inhibition
mixture contained a 0.1 M phosphate buffer, pH 7.4, enzyme (4.5 nM BChE or 0.2 nM AChE) tested
compound, and DTNB (0.3 mM; Sigma Chemical Co., St. Louis, MO, USA). Enzyme activity was
measured upon addition of ATCh (0.2 or 0.1 mM; Sigma Chemical Co., St. Louis, MO, USA) by the
Ellman method [45] at 25 ◦C and 412 nm, on a Tecan Infinite M200PRO plate reader (Tecan Austria,
GmbH, Salzburg, Austria). Due to the low solubility, a 100 mM stock solution of the tested compounds
was prepared in DMSO, and the same solvent was in controls as well. The IC50 values were determined
from at least three experiments by a nonlinear fit of the compound concentration logarithm values
vs.% of enzyme activity using Prism6 software (GraphPad Prism 6 Software, San Diego, USA).
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4. Conclusions
The photochemical synthesis resulted in four groups of molecules with different functionalities
on the methano-bridged benzobicyclo[3.2.1]octadiene skeleton. The majority of the compounds were
more selective for BChE than for AChE, although their inhibitory potency varied with compound
functionalities. The structure-activity relationship exhibited an increase in inhibition potency for
both enzymes by elimination of the endo-benzylamine substituent. Although none of the tested
compounds inhibited in nanomolar range, benzobicyclo[3.2.1]octene compounds 51 and 31 arose as
lead compounds for the future development of new AChE and BChE inhibitors, respectively. Therefore,
for future design of cholinesterase inhibitors and search for therapeutics of neurological disorders,
compounds with a benzobicyclo[3.2.1]octene skeleton, a hydroxyl group on it, and an opened furan
ring, should be taken into consideration.
Supplementary Materials: The following are available online. Figures S1–S31 with 1H NMR, 13C NMR, COSY,
LR COSY, and NOESY spectrum of prepared compounds, and Cartesian coordinates of optimized geometries of
reactants, transition states, and products of reactions 1–4.
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D.B.; biological activity measurements, T.Č. and N.M.H.; writing—original draft preparation, I.Š., D.B. and Z.K.;
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